EcoDrugPlus

Sem1 26s Proteasome Subunit

Ensembl ID : ENSNFUG00015022189
Gene Symbol: SEM1
1 Cross references
155 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSNFUG00015002865
Gene Symbol: TTK
3 Cross references
204 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSNFUG00015000920
Gene Symbol: UGCG
3 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSNFUG00015015377
Gene Symbol: WEE1
3 Cross references
205 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSNFUG00015005781
Gene Symbol: YES1
3 Cross references
208 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSNFUG00015012736
Gene Symbol: ACHE
1 Cross references
231 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSNFUG00015018841
Gene Symbol: ACVR2B
1 Cross references
195 Possible Orthologues:

Adenosine A1 Receptor B

Ensembl ID : ENSNFUG00015022998
Gene Symbol: ADORA1B
1 Cross references
173 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSNFUG00015018391
Gene Symbol: ADORA2A
3 Cross references
198 Possible Orthologues:

Adenosine A2a Receptor A

Ensembl ID : ENSNFUG00015021150
Gene Symbol: ADORA2AA
1 Cross references
189 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSNFUG00015006688
Gene Symbol: ADORA2B
3 Cross references
199 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSNFUG00015020601
Gene Symbol: ADA
3 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).